NEW
YORK, March 1, 2023 /PRNewswire/ -- Elevation
Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company
focused on the discovery and development of selective cancer
therapies to treat patients across a range of solid tumors with
significant unmet medical needs, today announced that management
will participate in the following investor conferences in
March:
Cowen 43rd Annual Health Care
Conference
Date: Tuesday, March
7
Panel Title: GI/GU Oncology
Panel Time: 12:50 p.m. ET
Oppenheimer 33rd Annual Healthcare
Conference
Date: Wednesday, March
15
Presentation Time: 8:00 a.m. ET
A live webcast and replay of the event will be available on the
Events page of the Company's Investor Relations website at
https://investors.elevationoncology.com.
About Elevation Oncology, Inc.
Elevation Oncology is
an innovative oncology company focused on the discovery and
development of selective cancer therapies to treat patients across
a range of solid tumors with significant unmet medical needs. We
are rethinking drug development by seeking out innovative,
selective cancer therapies that can be matched to a patient's
unique tumor characteristics. Our lead candidate, EO-3021, is a
potential best-in-class, antibody drug conjugate (ADC) designed to
target Claudin18.2, a clinically validated molecular target that
can selectively deliver a cytotoxic payload directly to kill cancer
cells. We are working to rapidly advance EO-3021 into the clinic in
the US across a range of solid tumor indications to demonstrate its
potential, as well as exploring other opportunities through new or
existing partnerships and business development opportunities to
expand our novel oncology pipeline. For more information, visit
www.ElevationOncology.com.
Elevation Oncology Investor and Media
Contact
Candice Masse,
978-879-7273
Senior Director, Corporate Communications & Investor
Relations
cmasse@elevationoncology.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-participate-at-upcoming-investor-conferences-301758509.html
SOURCE Elevation Oncology